NVO - EXCLUSIVE: Vivani Medical Outlines Plans To Kickstart First Clinical Study For Miniature GLP-1 Obesity Implant Program This Year | Benzinga
Vivani Medical Inc. (NASDAQ:VANI) expects to initiate the first clinical study for the NPM-115 program in Australia in the fourth quarter of 2024.
The NPM-115 clinical program will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.
LIBERATE-1 will be a randomized investigation of the safety, tolerability, and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight patients.
Related: Vivani Medical Highlights Weight Loss Data For GLP-1 Implant Supporting Potential Veterinary Use.
The study will enroll patients who will be titrated on weekly semaglutide injections for ...